COMPARISON OF IMMUNOHISTOCHEMISTRY, FISH, RTPCR METHODOLOGIES FOR DETECTION OF EML4-ALK FUSION GENE IN ADVANCED NON-SMALL CELL LUNG CARCINOMA

被引:0
|
作者
Han, Xiao-hong [1 ,2 ]
Ma, Li [3 ]
Liu, Yutao [3 ]
Zhang, Ningning [3 ]
Li, Dan [3 ]
Shi, Yuankai [3 ]
机构
[1] Chinese Acad Med Sci, Canc Hosp Inst, Med Oncol, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] Canc Inst, Med Oncol, Beijing, Peoples R China
关键词
NSCLC; Immunohistochemistry; Fluorescent in situ hybridization; RT-PCR; ALK;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
O-024
引用
收藏
页码:S453 / S454
页数:2
相关论文
共 50 条
  • [41] The Biology and Clinical Features of Non-small Cell Lung Cancers with EML4-ALK Translocation
    Pillai, Rathi N.
    Ramalingam, Suresh S.
    CURRENT ONCOLOGY REPORTS, 2012, 14 (02) : 105 - 110
  • [42] Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer
    Luo, Lian-Xiang
    Li, Ying
    Niu, Yu-Zhen
    Wang, Yu-Wei
    Wang, Qian-Qian
    Fan, Xing-Xing
    Xu, Jia-Hui
    Liu, Liang
    Leung, Elaine Lai-Han
    Yao, Xiao-Jun
    MEDCHEMCOMM, 2017, 8 (10) : 1914 - 1918
  • [43] Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers
    Lin, Eva
    Li, Li
    Guan, Yinghui
    Soriano, Robert
    Rivers, Celina Sanchez
    Mohan, Sankar
    Pandita, Ajay
    Tang, Jerry
    Modrusan, Zora
    MOLECULAR CANCER RESEARCH, 2009, 7 (09) : 1466 - 1476
  • [44] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Bilgin, Burak
    Sendur, Mehmet Ali Nahit
    Yucel, Sebnem
    Hizal, Mutlu
    Guner, Gurkan
    Akyurek, Nalan
    Erol, Cihan
    Akinci, Muhammed Bulent
    Dede, Didem Sener
    Yalcin, Bulent
    Kilickap, Sadettin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (09) : 2637 - 2643
  • [45] EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer
    Wang, Zhijie
    Zhang, Xuchao
    Bai, Hua
    Zhao, Jun
    Zhuo, Minglei
    An, Tongtong
    Duan, Jianchun
    Yang, Lu
    Wu, Meina
    Wang, Shuhang
    Wang, Yuyan
    Wu, Yilong
    Wang, Jie
    ONCOLOGY, 2012, 83 (05) : 248 - 256
  • [46] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Burak Bilgin
    Mehmet Ali Nahit Şendur
    Şebnem Yücel
    Mutlu Hizal
    Gürkan Güner
    Nalan Akyürek
    Cihan Erol
    Muhammed Bülent Akıncı
    Didem Şener Dede
    Bülent Yalçın
    Sadettin Kılıçkap
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 2637 - 2643
  • [47] Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC)
    Bauer, Todd M.
    Martini, Jean-Francois
    Besse, Benjamin
    Lin, Chia-Chi
    Soo, Ross A.
    Riely, Gregory J.
    Ou, Sai-Hong Ignatius
    Toffalorio, Francesca
    Abbattista, Antonello
    Thurm, Holger
    Camidge, D. Ross
    Kao, Steven
    Chiari, Rita
    Gadgeel, Shirish
    Felip, Enriqueta
    Shaw, Alice T.
    Solomon, Benjamin J.
    CANCER RESEARCH, 2020, 80 (16)
  • [48] ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer
    Fleschutz, Kathrin
    Walter, Lisa
    Leistner, Rumo
    Heinzerling, Lucie
    ANTICANCER RESEARCH, 2020, 40 (09) : 4937 - 4946
  • [49] A Case of Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion with Partial Response to Crizotinib
    Shen, Qian
    Kalyani, Farhin Shaheed
    Qu, Jingjing
    Chen, Zhen
    Zhang, Jing
    Zhou, Jianying
    CLINICAL LUNG CANCER, 2021, 22 (06) : E799 - E803
  • [50] Detection of EML4-ALK fusion gene expression in circulating tumor cells (CTCs) captured from non-small cell lung cancer (NSCLC) patients
    Park, Joo Kyung
    Ryu, Ji Kon
    Lee, Se-Hoon
    Kim, Eun-Hye
    Kim, Byung-Chul
    CANCER RESEARCH, 2014, 74 (19)